Company

Trince PLC

Trince develops cancer technologies using its LumiPore cell transfection platform.

About

Trince PLC develops cancer technologies and its LumiPore platform, which uses laser exposure and photothermal nanoparticles to temporarily permeabilize cell membranes. Founded in 2021 as a spin-off from Ghent University, the company is based in Asse, Belgium. It raised EUR 5.2 million in venture funding in December 2025.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in